Chicago—In patients with ALK-positive non-small cell lung cancer (NSCLC), the tyrosine kinase inhibitor (TKI) alectinib increases progression-free survival (PFS) by a year or more relative to crizotinib, according to a multinational trial. The head-to-head Phase III comparison of the TKIs was undertaken in treatment-naive patients with advanced disease.
The trial, called ALEX, “establishes alectinib (Alecensa, Genentech) as the new standard of care for initial treatment in this